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TRANSLATIONAL RELEVANCE 
 
Recent achievements in T cell immunology and molecular T cell receptor (TCR) 
engineering have enabled new approaches to utilize adoptive T cell transfer in clinical 
medicine. Despite evidence that renal cell carcinoma (RCC) is immunosensitive, the lack of 
therapeutically applicable T cells has hindered such advances for these patients. The TCR 
that we have identified has an exquisite specificity recognizing an antigen that is shared by 
more than 60% of RCC and 25% of other malignancies, while sparing normal cell 
counterparts. A transfer vector encoding the TCR sequences can be used as a generic 
reagent to imbue patient lymphocytes with antitumor function, including tumor-specific 
cytotoxicity and polyfunctional cytokine secretion. The identification of this new TCR 
specific for a broad panel of tumors expedites T cell-based immunotherapy to patients with 
RCC and other malignancies expressing the TCR-ligand. 
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ABSTRACT 
 
Purpose: Adoptive therapy with genetically engineered T cells carrying redirected antigen 
specificity is a new option to treat cancer. This approach is not yet available for metastatic 
renal cell carcinoma (RCC), due to the scarcity of therapeutically useful reagents. We 
analyzed tumor-infiltrating lymphocytes (TIL) from RCC to identify T cell specificities with 
shared tumor-specific recognition to develop T cell receptor (TCR)-engineered T 
lymphocytes for adoptive therapy of RCC.  
Experimental Design: We established a T cell clone from TIL that recognized an HLA-A2-
restricted tumor antigen. The TCR α- and β-chain genes were isolated, modified by codon 
optimization and murinization, and retrovirally transduced into peripheral blood lymphocytes 
(PBL). A TCR-expressing indicator line (B3Z-TCR53) was established to screen for antigen 
prevalence in RCC, other malignancies and normal cell counterparts.  
Results: TCR53-engineered PBL recapitulated the specificity of the TIL and demonstrated 
tumor-specific HLA-A2-restricted effector activites (IFN-γ, TNF-α, IL-2, MIP-1β, cytotoxicity). 
PBL-TCR53 of healthy donors and RCC-patients exhibited similar transduction efficiency, 
expansion and polyfunctional profile. Using B3Z-TCR53 cells, 130 tumor and normal cells 
were screened and shared TCR53 peptide:MHC expression was found in more than 60% of 
RCC and 25% of tumor lines of other histology, while normal tissue cells were not 
recognized.  
Conclusions: To date, TCR53 is the only TCR with shared HLA-A2-restricted recognition 
of RCC. It fulfills the criteria for utilization in TCR gene therapy and advances T cell-based 
immunotherapy to patients with RCC and other malignancies expressing the TCR-ligand. 
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INTRODUCTION 
 
The power of adoptive T cell therapy in tumor eradication is best demonstrated in chronic 
myeloid leukemia where allogeneic donor lymphocyte infusion following hematopoietic stem 
cell transplantation (HSCT) can result in patient cure (1). Other successful applications 
include the treatment of Epstein Barr Virus (EBV)-associated post-transplantation 
lymphoproliferative disease and EBV-associated cancers (2). The clinical success achieved 
in these malignancies is based on the expression of specific antigens by tumor cells, 
including minor histocompatibility antigens or tumor-associated viral antigens, which are 
targets for the adoptively transferred T lymphocytes. Recent data of three consecutive 
clinical trials of metastatic melanoma patients (3) give hope that solid tumors expressing 
non-viral antigens can also be successfully targeted by adoptive T cell therapy, if T cells 
with appropriate tumor-antigen specificity are identified. In these trials, remarkably high 
response rates of over 50% were achieved following the infusion of ex vivo expanded 
tumor-infiltrating lymphocytes (TIL) that were selected for their anti-tumor reactivity. Recent 
advances in genetic engineering now allow normal lymphocytes to be endowed with 
selected T cell receptor (TCR) genes (4), thus overcoming limitations due to poor 
proliferative capacity and poorly defined specificity of TIL. First clinical trials using TCR-
engineered T cells attested to the feasibility of this approach (5, 6).  
In renal cell carcinoma (RCC), a similar break-through has not yet occurred (7), although 
clinical data, including spontaneous remissions and the response to cytokine therapy (8-
10), suggest that these tumors are susceptible to immune-mediated effector mechanisms. 
Furthermore, T cells were found in tumors and blood of patients that had reactivity against 
RCC lines when tested ex vivo (11-20). Infusion of lymphokine-activated killer cells or TIL, 
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alone or in combination with interleukin-2 (IL-2), provided benefit for a few patients (21). 
Improved response rates were seen with allogeneic HSCT, but this therapy is linked with 
severe graft-versus-host disease due to the limited tumor specificity of infused cells ((22); 
and refs. in (7)). It is conceivable that clinical benefit could be further improved, if better 
suited T cells can be identified. However, there are few suitable T cell specificities to spur 
clinical development, as most RCC-reactive T cells proliferate poorly, recognize antigens 
expressed only by a small set of tumors, or use infrequent MHC-restriction elements (23-
26). This paucity is reflected by the fact that the only known TCR with broad RCC 
recognition is now undergoing clinical evaluation, even though it recognizes RCC in an 
unknown non-classical manner ((27), and 1). 
We used TIL as a source to isolate T cells that recognized RCC lines ex vivo (15). These T 
cells recognized naturally expressed RCC-associated antigens. For one T cell specificity, 
we also demonstrated that transfer of the TCR genes endowed normal lymphocytes with 
the same RCC-associated specificity (23). While this demonstrated proof of principle that 
transgenic TCR could be applied in RCC, the selected TCR recognized a unique ligand 
expressed only by the autologous tumor cells and, therefore, was not suitable for clinical 
development. 
Now we characterized a new TIL reactive against several RCC lines and isolated the TCR 
genes from one derived T cell clone. TCR expression in peripheral blood lymphocytes 
(PBL) transferred HLA-A2-restricted cytotoxicity and cytokine release. Further, by use of a 
TCR-engineered indicator cell line, we provide evidence that this TCR recognizes a broadly 
expressed ligand present on tumor cell lines, but not expressed by non-malignant primary 
cells, thus featuring hallmarks suitable for clinical development. 
                                                     
1 www.clinicaltrials.gov (NCT00870389) 
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MATERIAL AND METHODS 
 
Cells 
Cell lines (Table 1 and Table 2) were cultured in RPMI 1640 medium supplemented with 
10% FCS, 100 U/ml penicillin-streptomycin, 1 mM L-glutamine, 1 mM sodium pyruvate and 
1% non essential amino acids (CM). PBL and TIL were cultured in T cell medium (TCM; 
RPMI 1640 supplemented with 10% human serum, 100 U/ml penicillin-streptomycin, 1 mM 
L-glutamine, 1 mM sodium pyruvate, 1% non essential amino acids, and cytokines when 
indicated). Cells were incubated at 37°C and 6.5% CO2 in a humidified chamber. Primary 
normal kidney cells (NKC) are short-term cultures (passage 2 to 4) of cells from tumor-free 
kidney cortices obtained from RCC patients undergoing complete nephrectomy (Table 1). 
They were maintained in CM supplemented with 1% Insulin-Transferrin-Selenium-X. Plat-E 
packaging cells (28), 293T (ATCC: CRL-11268, American Type Culture Collection, 
Manassas, Virginia, USA), B3Z (29) and Jurkat 76 cells (30) were cultured as described 
(31, 32). Peripheral blood mononuclear cells (PBMC) were obtained from heparinized 
venous blood of healthy donors and RCC patients by Ficoll-Hypaque (Biochrom, Berlin, 
Germany) density gradient centrifugation. 
TIL-53 was isolated from a primary clear cell (cc) RCC tumor (T2N1MxG2-3, 6 cm) 
following the published procedure (33). TIL-53 was restimulated once with irradiated (100 
Gy) autologous IL-2-expressing RCC-53 (see ref. in (33)). On day 10 after stimulation, TIL-
53 was cloned by single cell dilution using IL-2-expressing RCC-53 cells (5x103, 100 Gy), 
allogeneic irradiated feeder PBL mixture (5x104, 50 Gy) and B-LCL cells (1.5x104, 100 Gy) 
in TCM supplemented with 100 U/ml rIL-2 and 2 ng/ml IL-7 (PromoCell GmbH, Heidelberg, 
Germany). After 20 days, T cell clones were transferred to 24-well plates and restimulated 
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with 6x104 IL-2-expressing RCC-53 cells, allogeneic irradiated feeder PBL (2x106), and B-
LCL cells (1x105). Unless otherwise indicated, all cell culture reagents were purchased from 
Invitrogen (Karlsruhe, Germany). The collection of blood and patient material was approved 
by the local ethics committee and donors gave informed consent. 
 
Transfection of HLA-A2 RNA into tumor and normal cells  
The plasmid pCDM8-HLA-A2 encoding HLA-A*0201 cDNA (kindly provided by E. Weiß, 
Munich, Germany) was linearized with NotI (Fermentas, Maryland, USA) and used as in 
vitro transcription template to produce RNA using the mMESSAGE mMACHINE T7 kit 
(Ambion, Austin, Texas, USA). Cells (2 x106) were resuspended in OptiMEM I medium 
(Invitrogen), placed in a 0.4 cm electroporation cuvette and briefly incubated on ice. RNA 
(15 µg, 200 μl) was added and electroporation was performed with Gene Pulser Xcell (Bio-
Rad Laboratories, Hercules, California, USA) at 400 V and 5 ms. Immediately after 
electroporation, cells were returned to culture medium and incubated for 24 h at 37°C and 
6.5% CO2. Cell surface expression was determined by flow cytometry using an HLA-A2-
specific antibody (ATCC: HB-54, see ref. in (23)). 
 
Isolation of TCR53 cDNA and construction of retroviral vectors 
Total cellular RNA was isolated from T cell clone TIL-53.29 using TRI Reagent (Molecular 
Research Center, Cincinnati, Ohio, USA). Applying repertoire analysis (34) in-frame 
TCRVα3.1, Vα19 and Vβ20 were identified (Arden nomenclature (35)). TCR53Vα19- and 
Vβ20-chain genes were amplified using gene-specific oligonucleotides, linked by a P2A 
peptide element to yield the transgene cassette 5’-TCRβ-P2A-TCRα-3’, and integrated into 
the retrovirus vector MP71-PRE (31, 36). This vector was designated MP71-TCR53. To 
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enhance TCR surface expression, the constant regions of both TCR chain genes were 
exchanged by their mouse counterparts (37) and ligated into MP71-PRE as indicated above 
(MP71-TCR53m). In addition, the transgene cassette of MP71-TCR53m was optimized for 
most frequent human codon usage, while avoiding cryptic splice sites and RNA instability 
motifs (GENEART, Regensburg, Germany (38)). This murinized and codon-optimized 
vector was designated MP71-TCR53mc. All constructs were verified by sequence analysis 
(MWG Biotech AG, Martinsried, Germany). Primer sequences will be provided on request. 
 
Production of TCR retroviruses and transduction of cells 
Amphotropic mouse leukemia virus (MLV)-pseudotyped retrovirus particles were produced 
by transient transfection of 293T cells using plasmids encoding Moloney-MLV-gag-pol, 
MLV-10A1-env, and MP71-TCR53, MP71-TCR53m or MP71-TCR53mc, as described (31). 
48 h after transfection, retroviral supernatant was harvested, filtrated and used for 
transduction of activated human PBL as described (31). TCR53 surface expression was 
determined at day 10 after transduction using anti-Vβ20-PE- (Immunotech, Marseille, 
France) and anti-CD8α-FITC-labeled antibodies (BD Pharmingen, Heidelberg, Germany). 
Ecotropic MLV-pseudotyped retroviruses were produced by transfection of Plat-E 
packaging cells (28) with MP71-TCR53m or Bullet-CD8α vector plasmids ((39), kindly 
provided by R. Debets, Rotterdam, The Netherlands) and applied to transduce B3Z cells. 
 
Generation of TCR53-expressing mouse B3Z indicator cells  
A TCR53-expressing mouse B3Z indicator cell line (B3Z-TCR53), which contains the 
bacterial β-galactosidase gene under the control of the minimal human IL-2 promoter with 
binding sites for the nuclear factor of activated T cells (29), was established by successive 
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transduction with the retrovirus vectors MP71-TCR53m and Bullet-CD8α. Expression of 
TCR53 and human CD8α was analyzed using TCR53-specific anti-Vβ20-PE- and anti-
CD8α-FITC-labeled antibodies. 24 h co-cultures with target cell lines were done in 96-well 
round bottom plates (BD Falcon) using 1x105 B3Z-TCR53 cells (E:T = 1:1). B3Z-TCR53 
cells were incubated with 1 µM ionomycin (Calbiochem, Darmstadt, Germany) and 5 ng/ml 
phorbol-12-myristate-13-acetate (PMA; Promega, Mannheim, Germany) for TCR-
independent stimulation. Supernatants of co-cultures were harvested and IL-2 content was 
determined by enzyme-linked immunosorbent assay (ELISA) following the manufacturer's 
protocol (eBioscience, San Diego, California, USA). Measurement of intracellular β-
galactosidase activity was performed as described (32). 
 
TNF-α quantification by WEHI cytotoxicity assay 
TIL (3x103 cells/100 µl) in TCM supplemented with 30 U/ml rIL-2 were added to adherent 
target cells (1.5x104/well) in 96-well flat bottom plates (BD Falcon). Where indicated, 4 µg of 
an anti-HLA-A2 antibody (ATCC: HB-54) was added. TIL and target cells cultivated alone 
were used to determine background TNF-α secretion. After 24 h, supernatants were 
collected and assayed for TNF-α content by measuring the cytotoxicity against WEHI 164 
clone 13 as described (40).  
 
Cytokine release assay and HLA-A2 blocking 
Co-cultures of TCR53 gene-modified PBL and target cells were performed as described 
(31) but using 1.5x104 target cells (E:T = 5:1). 24 h supernatants were harvested and 
analyzed for their IFN-γ content using ELISA (BD Biosciences). Antibody blocking of HLA-
A2 (ATCC: HB-54) was done as described (23). 
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Cytotoxicity 
Cell-mediated lysis of target cells by TCR53 gene-modified PBL was determined by a 
standard 4 h chromium release assay. Target cells were labeled for 1 h with 50 µCi sodium 
chromate-51 (Hartmann GmbH, Braunschweig, Germany) and incubated with TCR53-, 
GFP- or non-modified PBL using E:T ratios from 20:1 to 2.5:1 by employing 2x103 target 
cells, as described (23). All measurements were done as duplicates and K-562 and Daudi 
cells were used as controls. Data are shown as mean values ± mean deviation.  
 
Multi-parameter flow cytometry 
Cytokine secretion and degranulation analysis were performed using 2x105 PBL incubated 
with target cells at a ratio of 1:1 for 12 h. After 1 h, GolgiStop and Brefeldin-A (BD 
Biosciences) were added. Degranulation was detected by the addition of anti-CD107a-FITC 
and anti-CD107b-FITC during the stimulation phase. Membrane staining was performed 
with anti-CD45-Amcyan and anti-CD4-APC-A750 in FACS buffer (PBS, 2% FCS, 2 mM 
EDTA) for 20 min at 4°C, followed by addition of 7-amino-actinomycin-D (Sigma Aldrich, 
Seelze, Germany, 10 µg/ml, 20 min). Cells were fixed with 1% of paraformaldehyde (Merck, 
Darmstadt, Germany) for 20 min followed by permeabilization using two consecutive 
washes with 0.1% and 0.35% saponin (Sigma Aldrich). Intracellular staining was performed 
with anti-mouse-TCRβ-PE (detecting the mouse constant region of TCR53 β-chain), anti-
CD8-PacificBlue, anti-IFN-γ-PE-Cy7, anti-IL-2-APC and anti-TNF-α-A700 antibodies for 30 
min. All antibodies were purchased from BD Pharmingen. Data acquisition was done with 
LSRII (BD Pharmingen) and data were analyzed using FlowJo (TreeStar, Ashland, Oregon, 
USA). 
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RESULTS 
 
RCC-infiltrating T cells show broad tumor specificity and HLA-A2 restriction 
TIL, isolated from a primary ccRCC tumor of patient 53 (TIL-53, T2N1MxG2-3), displayed 
specificity for an antigenic epitope that is shared among RCC tumors and restricted by the 
MHC class I allotype HLA-A2 as demonstrated by blocking with an antibody directed 
against HLA-A2. Importantly, normal kidney cultures were not recognized by TIL-53 (Fig. 
1A, B). T cell receptor repertoire analysis of the TIL-53 population after three in vitro 
stimulations with autologous IL-2 secreting RCC-53 revealed oligoclonality with nine 
rearranged TCRVα and fourteen TCRVβ gene segments (not shown). Using limited dilution 
cloning, 106 T cell clones were recovered and 14 showed RCC-53 recognition. T cell clone 
TIL-53.29 recapitulated HLA-A2 restriction and the TIL-53 reactivity pattern when tested 
against selected target cells (Fig. 1C). Poor cell growth limited further detailed 
characterization of the parental TIL-53 and the derived T cell clone. TCR sequences of TIL-
53.29, revealed one in-frame TCRβ sequence Vβ20 (Arden nomenclature (35)), which in 
accordance to the IMGT data base (41) is TCRBV30*01-J2-5*01-D2*01 (CDR3: 
CAWSTLGYRETQYF) and two in-frame TCRα sequences Vα3.1 (TCRAV17*01-J21*01; 
CDR3: CDPNFNKFYF) and Vα19 (TCRAV41*01-J13*02; CDR3: CAAFFSGGYQKVTF). 
 
Enhanced surface expression and functional performance of modified TCR53 chain 
genes 
Since the sequence analysis of the TIL-53.29 cDNA revealed two TCRα and one TCRβ 
sequence, each TCRα-chain gene was combined with the TCRβ-chain gene in the 
retroviral vector MP71-PRE and used to transduce TCR-deficient Jurkat 76 cells. Here, only 
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the combination of TCRVα19 and TCRVβ20 genes resulted in surface expression of 
TCR53 (not shown). In primary human T cells, sufficient expression of this combination was 
only achieved when additional optimizations of the TCR sequences were performed. 
Replacement of human constant regions by mouse counterparts (murinization, TCR53m) or 
murinization and codon optimization (TCR53mc) yielded improved TCR expression. 
Transduction of primary human T cells using titer-equilibrated MP71-TCR53 variants 
resulted in 9% (MFI 79) of CD8+TCRVβ20+ cells when the non-modified TCR53 was 
applied, while TCR53m and TCR53mc yielded 19% (MFI 95) and 38% (MFI 228) of 
CD8+TCRVβ20+ cells, respectively (Fig. 2A). Importantly, TCR53 sequence optimization 
clearly improved functionality of engineered PBL, as seen by superior target-specific 
cytokine response of PBL transduced with MP71-TCR53mc (Fig. 2B). 
 
TCR53 gene-modified PBL show tumor-associated multi-functionality 
To further evaluate that the TCR53 antigen specificity could be transferred, PBL of healthy 
donors were transduced with MP71-TCR53mc and the specificity of TCR53 gene-modified 
T cells was determined in a cytotoxicity assay using different HLA-A2+ or HLA-A2- tumor 
cell lines or primary kidney cultures. As shown in Figure 2C, TCR53-transduced PBL (PBL-
TCR53) showed specific lysis of HLA-A2+ RCC lines, exemplarily shown for RCC-26, RCC-
53, CCA-17, MZ-1257, and tumor cell lines of glioblastoma (U-373) and squamous cell 
carcinoma (UT-SCC-15). The specific lytic activity against the HLA-A2-transfected RCC line 
KT-195 (KT-195/A2+), but not the parental HLA-A2- KT-195 cell line confirmed the HLA-A2 
restriction of PBL-TCR53. Primary cultures of HLA-A2+ normal kidney cells (NKC) were not 
recognized, exemplarily shown are NKC-26 and NKC-42 (Fig. 2C). The cytotoxicity was 
TCR53-mediated, as GFP- and non-transduced PBL showed no lytic activity. Furthermore, 
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PBL-TCR53 secreted IFN-γ only in response to the HLA-A2+ RCC-26, CCA-17 and UT-
SCC-15, but not in response to the HLA-A2+ normal kidney line NKC-26. IFN-γ secretion 
was blocked by anti-HLA-A2 antibody (ATCC: HB-54), but not by an isotype control 
antibody, attesting the HLA-A2 restriction (Fig. 2D).  
The secretion of cytokines was studied using a Multiplex bead assay system that included 
the simultaneous measurement of IFN-γ, TNF-α, IL-2 and MIP-1β. All four cytokines were 
detected in supernatants of PBL-TCR53 co-cultured with TCR53 p:MHC-ligand positive 
tumor cells, but were absent in co-cultures with TCR53 p:MHC negative cells or PBL-GFP 
(Fig. S1), thus demonstrating specificity and a strong pro-inflammatory response profile of 
PBL-TCR53. 
Using flow cytometry for cytokine secretion (IFN-γ, TNF-α, IL-2) and lytic granule exocytosis 
(CD107), the polyfunctional effector response of PBL-TCR53 was analyzed on a single cell 
level. RCC-26 cells were used as target cells. Antibody specific for the mouse constant 
region of the TCR53 β-chain was included in the multi-chromatic staining to evaluate 
whether the observed effector functions were performed by T cells expressing the 
transgenic TCR53. Stimulation with RCC-26 caused CD8+ T cells to degranulate and 
secrete cytokines TNF-α, IFN-γ and IL-2 (Fig. 3A, left panels, black and green populations). 
The majority of the responding CD8+ T cells carried the TCR53 receptor (Fig. 3A, green 
population). The most prominent effector activities of PBL-TCR53 were lytic granule release 
(CD107+: 28%) and IFN-γ secretion (29%) followed by IL-2 (22%) and TNF-α (19%, Fig. 3A, 
left panels, green population). Non-transduced PBL showed very low background activity 
(Fig. 3A, right panels). Boolean gating analysis of the responding CD45+CD8+TCR53+ T cell 
population (Fig. 3B, C) revealed high polyfunctionality with 55% of the responding TCR53+ 
T cells displaying 2 or more functions, including the secretion of IL-2. The multi-functional 
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response of PBL-TCR53 was similar to PBL which were transgenic for an HLA-A2-
restricted tyrosinase369-377 peptide-specific TCR (TCR-D115, (42), data not shown). 
 
TCR53 is efficiently expressed and highly functional in PBL of RCC patients 
Next, we investigated the transduction efficacy and functional profile of PBL of five RCC-
patients (Fig. S2 and not shown). All patients had progressive metastatic disease and two 
of them had received several applications of IFN-α and 5-fluorouracil prior to blood 
donation. Despite the poor clinical status and the exposure to immuno- and 
chemotherapeutics, PBL were efficiently transduced with TCR53 (Fig. S2A), displayed 
tumor-specific lytic activity (Fig. S2A, B) and multifunctionality profiles that were 
indistinguishable from those of PBL-TCR53 of healthy donors (Fig. 3, Fig. S2C). TCR53-
transduced PBL of healthy donors and patients could be successfully expanded ex vivo 
following the protocol utilized for clinical application ((6), Fig. S2A) and were highly lytic and 
polyfunctional on day 20 of expansion (not shown). 
 
Specific recognition of TCR53 p:MHC ligand by the indicator cell line B3Z-TCR53 
An indicator cell line, based on the mouse hybridoma B3Z, was generated to evaluate the 
distribution of the p:MHC ligand specifically recognized by TCR53. By retroviral transfer, the 
genes encoding the human CD8α chain and the TCR53 chains were introduced into B3Z 
cells. Transduced cells (B3Z-TCR53) showed stable expression of human CD8α and 
TCR53Vβ20 (Fig. 4A, grey curves). These cells secreted IL-2 after incubation with TCR53 
p:MHC+ RCC-26 and RCC-53 tumor cell lines, but not after co-culture with NKC-26, which 
is TCR53 p:MHC- (Fig. 4B). This recognition profile could be confirmed by measuring the 
intracellular activity of β-galactosidase (Fig. 4C). As B3Z-TCR53 cells were not stimulated 
RCC-reactive TCR with shared antigen specificity 
 
 
16
in the absence of human CD8α, recognition of the antigenic p:MHC complex is CD8 
dependent (Fig. 4B and 4C). 
 
High incidence of TCR53 p:MHC in RCC cells and in tumor cells of other histology 
B3Z-TCR53 cells were used to determine the frequency of TCR53 p:MHC ligand 
occurrence in RCC and tumors of other histologies as well as in non-transformed cell lines 
of normal tissue. Twelve of 19 (63%) HLA-A2+ RCC cell lines tested were found to stimulate 
IL-2 secretion after co-culture with B3Z-TCR53 cells above background (B3Z-TCR53 alone 
(12 pg/ml), Fig. 4D, Table 1). Furthermore, HLA-A2- RCC cell lines were transfected with 
HLA-A2 mRNA and HLA-A2 expression was confirmed by flow cytometry (not shown). After 
co-culture of these HLA-A2-transfected cells with B3Z-TCR53 cells, 7 of 11 RCC lines 
(64%) induced IL-2 secretion (Fig. 4D, Table 1). Fifteen of the 30 HLA-A2+ RCC lines are 
known ccRCC (Table 1, (43), (44) and personal communication); none of the remaining are 
of defined non-cc histology. B3Z-TCR53 recognition was observed for 11 (73%) of the 
ccRCC and 9 (60%) of the unknown RCC-histology. Cell lines 768-0 and A498 are 
examples of ccRCC with von-Hippel-Lindau (VHL)-inactivating mutations. Both cell lines 
stimulated B3Z-TCR53 cells to secrete IL-2, as did the 786-0 variant that expressed VHL-
wild-type after stable transfection ((44), Table 1). Among the 15 known ccRCC, four were 
not recognized by B3Z-TCR53 cells, suggesting that the presence of the TCR53  epitope is 
not necessarily linked to the cc histology. 
In addition, HLA-A2+ tumor lines of other origin (25%), like B-lymphoblastoid cells (LCL-1, 
LCL-4) and B-lymphocytic lymphoma (NALM-6, SKW-6, GRANTA-519), brain tumor lines 
(U-373, SK-NSH, U-251MG), melanoma (BLM), pancreatic adenocarcinoma (PANC-TU1), 
and squamous cell carcinoma (UT-SCC-15) were able to stimulate the indicator cell line 
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(Fig. 4D, Table 2). Furthermore, 24 normal cell cultures, which either expressed HLA-A2 
naturally or after mRNA transfection, were tested for TCR53 p:MHC ligand expression. 
These included 16 HLA-A2+ NKC, seven PBMC and one endothelial cell culture. Only one 
of the normal cells (NKC-33) induced marginal IL-2 secretion (Table 1 and Table 2). 
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DISCUSSION 
 
We characterized T cells infiltrating RCC tumors and defined various reactivity patterns, 
including both MHC-restricted and non-MHC-restricted specificities (15). The poor 
proliferative capacity of most TIL precluded their further development into clinically 
applicable reagents. Technological advances in TCR transfer overcome constraints of poor 
proliferation and T cells with desired specificities can be generated through recovery of their 
TCR sequences from T cell clones. In our studies of various RCC infiltrates, we identified 
one TIL population that displayed the necessary requirements for clinical application, 
including HLA-A2 restriction and recognition of a shared antigen expressed by RCC that 
was absent in normal kidney cells. The limited growth capacity of the parental TIL-53 and a 
derivative T cell clone, TIL-53.29, was overcome through TCR cloning and transfer into 
recipient lymphocytes. Thereby, unlimited numbers of T cells became available to perform 
functional testing of recognition of tumor and non-tumor cell lines. The results of these 
extensive specificity studies revealed the potential clinical value of this HLA-A2-restricted 
TCR for use in adoptive T cell therapy.  
However, the wild-type TCR53 was poorly expressed in PBL and modification of the TCRα- 
and β-chain sequences, particularly the use of both murinization (37) and codon 
optimization (38), was required for efficient cell surface expression and functionality. This is 
in agreement with recently published data regarding several other TCR, which were only 
efficiently expressed to yield TCR gene-modified T cells with high functional avidity after 
optimization of the TCR genes (4). 
To achieve clinical efficacy in adoptive T cell therapy, it is essential that TCR-transgenic T 
cells show highly specific tumor recognition while ignoring normal cells. In addition, they 
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should mediate multiple effector functions, including tumor cell lysis and cytokine secretion 
which, in turn, can activate other accessory components of the immune system. Indeed, 
recent studies have shown that the capacity of a T cell population to simultaneously exert 
multiple effector functions is an essential requirement for effective immune responses (45, 
46). The transfer of optimized TCR53 genes enabled PBL to mediate highly effective lysis 
of various tumor cell lines. This was accompanied by the production of TH1 cytokines and 
the secretion of IL-2, parameters that were recently described as characteristic markers of 
optimally effective T cells (46). Further analysis by multi-parameter flow cytometry revealed 
that the majority of T cells exhibited two or more effector functions simultaneously. The 
functional response of PBL-TCR53 was restricted to tumor cells, while cells of normal 
tissues were not recognized. Since TCR53 gene-modified T cells of several healthy donors 
achieved high functionality, this TCR can be considered as an effective reagent to redirect 
T cell specificity. PBL of RCC-patients were also efficiently transduced with TCR53 and had 
similar lytic and polyfunctional profile than PBL-TCR53 of heathy donors. All PBL-TCR53 
could be expanded to high numbers ex vivo and maintained the multifunctional response 
profile, thus displaying qualities imperative to therapeutic application.  
Another important parameter to judge the potential therapeutic value of a TCR is the 
prevalence of TCR ligand expression among tumor cells. The generation of an indicator cell 
line based on the co-expression of human CD8α and TCR53 in mouse B3Z hybridoma cells 
allowed extensive screening of a large panel of tumor and normal cell cultures. We 
analyzed 130 cell lines and primary cells from different histologies, including 41 RCC, 18 
hematopoietic malignancies, 10 melanoma, 9 sarcoma, 7 brain tumor lines, 5 colon 
carcinoma, 4 squamous carcinoma, 3 of each prostate carcinoma, and breast carcinoma, 
and 2 pancreatic carcinoma, as well as 20 primary cultures of normal kidney tissues, 7 
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hematopoietic and 1 endothelial cells. This screening recapitulated the original TIL-53 
specificity and firmly established: (i) HLA-A2 restriction, (ii) shared expression of the TCR53 
p:MHC ligand in 63% of RCC and 25% of other tumor entities, and (iii) tumor selectivity with 
only one of 24 HLA-A2+ normal cells being marginally recognized. CcRCC is the most 
common type of RCC and has in most cases characteristic VHL-inactivating mutations that 
are not found in non-ccRCC or tumors of other histologies (9, 44). In our panel, 11 of 15 
HLA-A2+ ccRCC lines (73%) were recognized by B3Z-TCR53 cells. Due to the absence of 
RCC with defined non-cc histologies our panel does not allow an assumption on the TCR53 
antigen prevalence in ccRCC versus RCC of non-cc histology. It is, however, very unlikely 
that the TCR53 epitope is derived from VHL, as RCC with mutant VHL, or transfected wild-
type VHL, were equally well recognized. Moreover, other tumor cell lines and normal cells, 
which mostly have wild-type VHL, were generally not recognized by TCR53. Among the 
non-RCC tumors, the TCR53 p:MHC ligand expression was frequently found in malignant B 
cell lines and B-LCL (5/13, 38%), whereas there was no evidence of expression in 
sarcomas, prostate and breast carcinomas. Malignant T cell lines were not included in our 
analysis. Treatment of tumor cells with IFN-α, but not IFN-γ, enhanced TC53-p:MHC-ligand 
expression. Unlike IFN-γ, IFN-α did not increase levels of HLA-A2, thus it apparently 
regulates TCR53-p:MHC ligand expression either by increasing antigen expression levels 
or by improving antigen processing independently of MHC-class I (not shown).  
At present, the molecular nature of the TCR53-stimulatory antigen is not known. A screen 
(using peptide-loaded T2 cells and ELISPOT) of several common epitopes with predicted 
HLA-A2 binding motifs that were found by others to be frequently over-expressed in RCC 
compared with normal kidney tissues, including G250 (47), Her2/neu, WT-1, MUC-1, 
hTERT, VEGF, various MAGE epitopes and survivin (peptide sequences see (48)) was 
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negative. Additionally, the TCR53 recognition pattern of RCC cell lines did not coincide with 
HERV-E expression (defined by PCR, (26)) and B3Z-TCR53 cells did not recognize the cell 
line (HT-29), which is positive for the commonly RCC-expressed 5T4 antigen (49, 50). From 
these data, we conclude that the epitope recognized by TCR53 is different from those 
presently known for RCC. The identification of this new tumor-associated antigen is now 
feasible through the use of TCR gene transfer to generate sufficient cell numbers for the 
screening procedure. 
At present, immunotherapeutic options are limited for the treatment of metastatic RCC. For 
adoptive therapy of melanoma (3, 5, 6) several candidate TCR are currently under clinical 
evaluation. The here described TCR53, is the first TCR with HLA-A2-restricted shared 
recognition of RCC. With its broad tumor-specific multi-functional response, that includes 
the secretion of IL-2, and the restriction by the prevalent HLA-A2 class I molecule, TCR53 
gene-modified T cells are well suited for adoptive T cell therapy. TCR53 complements the 
recently described TCR with a non-classical RCC recognition (27), offering the therapeutic 
option to target RCC tumors through MHC-restricted and non-restricted effector 
mechanisms, thereby limiting immune escape for patient benefit. In the clinical situation, the 
B3Z-TCR53 indicator cell line can be employed to screen biopsies to identify TCR53-
p:MHC ligand expression on tumor cells, enabling individualized application of TCR53 
gene-modified T cells to those patients with TCR53-p:MHC ligand positive tumors who will 
most likely benefit from the therapy. The specific up-regulation of TCR53 p:MHC ligand 
expression on tumor cells by IFN-α suggests that adoptive T cell therapy with TCR53 gene-
modified T cells could be usefully combined with IFN-α treatment, a practised therapy of 
RCC that achieves approx. 15% response rates (10), to improve clinical benefit. 
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renal cell carcinoma cells  renal cell carcinoma cells 
786-O § - + 63  RCC-26 + - 267 
A-498 § + - 52  RCC-36 + - 720 
CCA-1 - - ≤12  RCC-53 + - 60 
CCA-1 - + 191  SKRC-12 - - ≤12 
CCA-7 - - ≤12  SKRC-12 - + 61 
CCA-8 - - ≤12  SKRC-17 + - ≤12 
CCA-8 - + ≤12  SKRC-28 - + ≤12 
CCA-9 - - ≤12  SKRC-38 - + ≤12 
CCA-9 - + 102  SKRC-44 + - ≤12 
CCA-13 - - ≤12  SKRC-59 + - ≤12 
CCA-17 + - 433  normal kidney cells 
CCA-23 - - ≤12  NKC-2 + - ≤12 
CCA-23 - + 21  NKC-3 + - ≤12 
CCA-29 + - ≤12  NKC-4 + - ≤12 
KT-2 + - 20  NKC-6 - - ≤12 
KT-13 + - 34  NKC-7 + - ≤12 
KT-15 + - 152  NKC-26 + - ≤12 
KT-30 + - 19  NKC-32 - - ≤12 
KT-53 + - 21  NKC-33 + - 19 
KT-111 + - ≤12  NKC-36 - + ≤12 
KT-187 - - ≤12  NKC-37 + - ≤12 
KT-187 - + ≤12  NKC-38 - + ≤12 
KT-195 - - ≤12  NKC-39 - + ≤12 
KT-195 - + 137  NKC-40 - - ≤12 
MZ-1257 + - 61  NKC-40 - + ≤12 
MZ-2175 - - ≤12  NKC-41 - + ≤12 
MZ-2175 - + 555  NKC-42 + - ≤12 
RCA-1770 - - ≤12  NKC-43 + - ≤12 
RCC-1.11 + - ≤12  NKC-47 - - ≤12 
RCC-1.24 + - 70  NKC-49 + - ≤12 
RCC-1.26 + - ≤12  RPTEC * - + ≤12 
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TCR53 p:MHC ligand prevalence among RCC and NKC 
B3Z-TCR53 were co-cultured with indicated cells and IL-2 values are listed (12 pg/ml was the background 
value of B3Z-TCR53 cells alone). Cell lines were collected through laboratory exchanges or generated locally. 
CCAs (provided by Gerharz et al. (42)), as well as 786-0, A498, MZ-1257, RCC-1.11, RCC-1.24, RCC-1.26, 
RCC-26, RCC-36 and RCC-53 are of known cc histology. (§) indicates RCC with described VHL-inactivating 
mutations. A variant of 786-0 expressing the wild-type VHL after transfection (786-0 VHLwt8, provided by W. 
Kaelin, (43)) induced similar amounts of IL-2 than its VHL-/- parental line 786-0 (46 pg/ml; not shown). NKC 
are short-term cultures of cells of tumor-free kidney cortices. HLA-A2 transfection was performed using RNA. 
The HLA-A2 status of all cell lines and cultures was confirmed by flow cytometry. (*) RPTEC 2814-3 is a 
primary renal proximal tubular epithelial cell purchased from BioWhittaker, Walkersville, Maryland, USA. 
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other tumor cells (origin)  other tumor cells (origin) 
624.38 (1) + - ≤12  LCL-4 (11) + - 25 
93.04-A12 (1) + - ≤12  LCL-26 (11) + - ≤12 
A-375 (1) + - ≤12  LNCAP (7) + - ≤12 
A-673 (2) + - ≤12  MACA-1 (12) - - ≤12 
BLM (1) + - 56  MACA-1 (12) - + ≤12 
BOE (3) - - ≤12  MCF-7 (12) + - ≤12 
BOE (3) - + ≤12  MG-63 (2) - - ≤12 
CCL-121 (2) - - ≤12  NALM-6 (3) + - 49 
COLO-205 (4) + - ≤12  PANC-TU1 (5) + - 136 
COLO-357 (5) - - ≤12  PC-3 (7) - + ≤12 
CRL-1543 (2) + - ≤12  PCI-1 (8) + - ≤12 
CRL-1544 (2) + - ≤12  SAO-S2 (2) + - ≤12 
D-283 (6) - - ≤12  SK-23 (1) + - ≤12 
D-458 (6) - - ≤12  SK-MEL25 (1) + - ≤12 
DU-145 (7) - + ≤12  SK-MEL29 (1) - - ≤12 
EWING-AK (2) - - ≤12  SK-MEL29 (1) - + ≤12 
FADU (8) - - ≤12  SK-NSH (10) + - 39 
FADU (8) - + ≤12  SKW-6 (3) + - 35 
GRANTA-519 (3) + - 350  SW-480 (4) + - ≤12 
HBL-2 (3) - + ≤12  SW-620 (4) + - ≤12 
HT-29 (4) - + ≤12  TC-71 (2) + - ≤12 
HTC-116 (4) + - ≤12  THP-1 (9) + - 13 
JEKO-1 (3) + - ≤12  U2-OS (2) + - ≤12 
JVM-2 (3) - + ≤12  U-87 (13) + - ≤12 
K-562 (9) - - ≤12  U-251MG (14) + - 45 
K-562 (9) - + ≤12  U-373 (13) + - 155 
KARPAS-422 (3) + - ≤12  UT-SCC-15 (8) + - 313 
KELLY (10) - - ≤12  WM-115 (1) + - ≤12 
L-428 (3) - - ≤12  WM-226.4A (1) + - ≤12 
LCL-1 (11) + - 57  other normal cells (origin) 
LCL-2 (11) + - ≤12  BMEC (15) + - ≤12 
LCL-3 (11) + - ≤12  PBMC1-7 § (16) + - ≤12 
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TCR53 p:MHC ligand prevalence among tumor and normal cells other than RCC or NKC 
B3Z-TCR53 were co-cultured with indicated cells and IL-2 values are listed (12 pg/ml was the background 
value of B3Z-TCR53 cells alone). Cell lines were collected through laboratory exchanges. HLA-A2 
transfection was performed using RNA. HLA-A2 status was determined by flow cytometry. The numbers in 
parenthesis after the cell name indicate the histologic origin: (1) melanoma, (2) sarcoma, (3) B-lymphocytic 
leukemia/lymphoma, (4) colon carcinoma, (5) pancreas carcinoma, (6) medullablastoma, (7) prostate 
carcinoma, (8) squamous carcinoma, (9) myelocytic leukemia, (10) neuroblastoma, (11) EBV-B-
lymphoblastoid cell line, (12) breast carcinoma, (13) glioblastoma, (14) astrocytoma, (15) brain microvascular 
endothelial cells, (16) peripheral blood mononuclear cells (§ of seven different donors). 
RCC-reactive TCR with shared antigen specificity 
 
 
33
FIGURE 1 
HLA-A2-restricted recognition of RCC by TIL-53 and 
T cell clone TIL-53.29 
TIL-53 (A) or TIL-53.29 cells (C) were co-cultured with 
indicated tumor cells lines in the presence of HLA-A2 
blocking antibody or an isotype control antibody for 24 
h. Recognition of target cells was determined in a WEHI 
assay. Results are expressed as TNF-α ± mean 
deviation of triplicates. nd = not done. (B) Shown is the 
summarized screen of renal cell carcinoma (RCC) cell 
lines and normal kidney cells (NKC) by using TIL-53. 
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FIGURE 2 
Enhanced cell surface expression of optimized TCR53 genes and functionality of TCR53-transduced 
PBL 
(A) FACS  analysis of untransduced PBL (PBL) or PBL transduced with the retrovirus vector MP71-PRE 
encoding TCRα- and β-chain cDNAs linked by the P2A element using wild-type TCR53 genes (TCR53), 
murinized (TCR53m) or murinized and codon optimized (TCR53mc) variants. TCR53β-chain expression was 
determined using an anti-Vβ20-specific antibody. Numbers represent the percentage of Vβ20+CD8+ T cells, 
MFI values refer to the Vβ20 intensity of these cells. Shown is one representative experiment of three. (B) 
PBL, PBL transduced with MP71-TCR53, MP71-TCR53m or MP71-TCR53mc were co-cultured with RCC-53 
and IFN-γ release was determined by ELISA. Bars are the mean of duplicates ± mean deviation. Shown is 
one representative experiment of three. (C) Cell-mediated cytotoxicity of titered numbers of MP71-TCR53mc-
transduced PBL (circles, transduction efficiency: 20%), GFP-transduced PBL (triangle) or untransduced PBL 
(squares) against HLA-A2+ RCC tumor cell lines (RCC-26, RCC-53, CCA-17, MZ-1257), cell lines of other 
tumor histology (glioblastoma (U-373), squamous cell carcinoma (UT-SCC-15)), HLA-A2+ normal kidney cells 
(NKC-26, NKC-42), HLA-A2- (KT-195) RCC tumor lines and HLA-A2-transfected KT-195 cells (KT-195/A2+). 
Percent specific lysis values are means of duplicates ± mean deviation. E:T ratio refers to the total CD3 cell 
number. (D) IFN-γ secretion using PBL-TCR53 in the presence or absence of HLA-A2 blocking antibody or an 
isotype control antibody. Bars represent mean values of duplicates ± mean deviation. Experiments were 
repeatedly done with PBL of four different donors. One set of representative data is shown. 
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FIGURE 3 
TCR53 gene-modified PBL of healthy donors and 
RCC-patients show complex effector responses 
against TCR53 p:MHC expressing cell lines 
(A) TCR53 gene-modified or non-transduced PBL of 
one healthy donor and RCC-patient #1 were used on 
day 9 after TCR-transduction to analyze the 
polyfunctional response profile. Transduced PBL were 
incubated with TCR53 p:MHC+ RCC-26 and analyzed 
for cytokines (IFN-γ, TNF-α, IL-2) and lytic granule 
release (CD107) in an 8-color combination staining. T 
cells were selected using CD45. Dot plots of the gated 
CD45+CD8+ T cells (black) or CD45+CD8+TCR53+ T 
cells (green) display two functional parameters. 
Numbers indicate the percentage of cells within the 
respective quadrant. (B, C) Results of boolean gating 
analysis for the responding CD45+CD8+TCR53+ T cells 
after co-culture with RCC-26 are shown. The pie chart 
(shown in B) summarizes the fractions of PBL-TCR53 
showing one, two, three or four functional responses. 
Similar results were obtained with PBL of other healthy 
donors and RCC patients (Fig. S2) and when using 
other TCR53 p:MHC+ tumor cell lines for stimulation 
(not shown). 
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FIGURE 4 
Specificity of the B3Z-TCR53 indicator cell line and prevalence of the TCR53 p:MHC ligand among 
tumor cell lines and cells of normal tissues 
(A) Surface expression of human CD8α and TCR53Vβ20 on B3Z-TCR53 cells was detected by flow 
cytometry. Numbers indicate the percentage of Vβ20+ or human CD8α+ B3Z cells (grey curves). (B) B3Z-
TCR53 cells transduced or non-transduced with human CD8α were co-cultured alone (w/o) or with cell lines 
RCC-26, RCC-53 and NKC-26 for 24 h. B3Z-TCR53 cells were incubated with ionomycin and PMA for TCR-
independent stimulation (Max). IL-2 concentration of supernatants was determined by ELISA. Bars represent 
the mean of duplicates ± mean deviation. (C) B3Z-TCR53 cells were co-cultured as in (B), fixed, and β-
galactosidase was detected by X-Gal staining. (D) B3Z-TCR53 cells were co-cultured with indicated tumor cell 
lines and cells of normal tissues for 24 h and IL-2 production was quantified by ELISA. The dashed line 
indicates IL-2 background level produced by the indicator cell line alone (12 pg/ml). Each dot represents the 
IL-2 value of B3Z-TCR53 cells after co-culture with one specific cell line (see Table 1 and Table 2) of the 
group: RCC, renal cell carcinoma (n = 41); other tumors (n = 61); NKC, normal kidney cells (n = 20); ntc: non-
tumor cell lines (n = 8). For each group, HLA-A2+ (closed), HLA-A2-transfected (grey), and HLA-A2- (open) 
cells are shown. For individual results see Table 1 and Table 2. 
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SUPPLEMENTARY METHODS 
 
Multiplex cytokine assay 
The supernatants from cytotoxicity assays (E:T = 10:1) were measured for cytokine content 
using a custom-mixed human Multiplex bead assay system and Luminex xMAP Technology 
(Bio-Plex System, Bio-Rad, München, Germany) allowing simultaneous detection of 
cytokines IFN-γ , TNF-α, IL-2 and MIP-1β. Data analysis was done using the Bio-Rad Array 
Operation System and applying five parameter logistic regression algorithms. 
RCC-reactive TCR with shared antigen specificity 
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SUPPLEMENTARY FIGURE 1 
TCR53 gene-modified PBL show pro-inflammatory cytokine response 
PBL-TCR53 were co-cultured with indicated tumor cell lines and supernatants were tested for their cytokine 
content using Bio-Plex cytokine assay allowing simultaneous detection of IFN-γ , TNF-α, IL-2 and MIP-1β. A 
set of representative data is shown. 
RCC-reactive TCR with shared antigen specificity 
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SUPPLEMENTARY FIGURE 2 
PBL-TCR53 of healthy donors and RCC-patients show equivalent T cell expansion and functional 
response 
PBL were obtained from a healthy donor and three RCC-patients who had progressive metastatic disease. 
For transduction, PBL of the healthy donor and patients were defrosted from liquid nitrogen, stimulated and 
transduced as described (see Material and Methods, main manuscript). Transduced PBL were expanded with 
anti-CD3 (ATCC: CRL-8001 (OKT 3), kindly provided by E. Kremmer) and anti-CD28 antibodies (Becton 
Dickinson) in TCM containing 300 U rIL-2/ml (Cetus, Emeryville, USA). Cells were used for functional assays 
on day 9 and 20 (not shown) after transduction, with similar results achieved on both time points. (A) 
Summary of TCR53 transduction efficiency, T cell expansion, lytic response and clinicopathologic patient 
characteristics (TMN status). Patient #1 (detailed shown in Fig. 3, main manuscript) was enrolled in an 
immuno-chemotherapy treatment program and the PBL were harvested after the patient had received 5 
cycles of IFN-α and 5-fluorouracil. The transduction efficiency (% TCR53+) is expressed as the percentage of 
mTCR+ PBL determined on day 4 after transduction. The fold-expansion is the relative increase in cell number 
between day 0 (1x106 cells) and day 9. The lysis refers to the cytotoxic value against RCC-26 at an E.T ratio 
of 20:1. (B) Shown is the cell-mediated cytotoxicity of untransduced and TCR53-transduced PBL against RCC 
tumor lines RCC-26 (p:MHC+) and KT-195 (HLA-A2-). Percent specific lysis values are means of duplicates ± 
mean deviation. E:T ratio refers to the total CD3 cell number. (C) The graph depicts the percentage of 
responding T cells showing 1, 2, 3, or 4 functional responses simultaneously. The values were obtained 
through boolean gating analysis gated on the CD45+CD8+TCR53+ cells from 8-color flow cytometry as 
described in Material and Methods (main manuscript). Dot plots and details of the polyfunctional response of 
healthy donor and patient #1 are shown in Fig. 3 (main manuscript). 
